OPEN END-TURBO-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - BOERSE MUENCHEN 15:35:56 2024-06-28 EDT | ||
| 2.88 EUR | -0.69% |
|
| Current month | +7.46% | ||
| 1 month | +9.92% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 2.88 | -0.69% |
| 24-06-27 | 2.9 | 0.00% |
| 24-06-26 | 2.9 | +1.05% |
| 24-06-25 | 2.87 | -1.03% |
| 24-06-24 | 2.9 | +1.40% |
Real-time BOERSE MUENCHEN
Last update June 28, 2024 at 03:35 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | HSBC |
| WKN | TR0YFT |
| ISIN | DE000TR0YFT6 |
| Date issued | 2017-10-16 |
| Strike | 165.1 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 0.38 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.98 € |
|---|---|
| Lowest since issue | 0.26 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Certificates
- Certificat
